Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 22, 2022


BioSig Technologies, Inc.

(Exact name of registrant as specified in its charter)





(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)


Identification No.)


55 Greens Farms Road

Westport, Connecticut



(Address of principal executive offices)


(Zip Code)


(203) 409-5444

(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class


Trading Symbol(s)


Name of exchange on which registered

Common Stock, par value $0.001 per share




The NASDAQ Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 5.02         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On April 22, 2022, Anthony Zook resigned from the board of directors (the “Board”) of BioSig Technologies, Inc. (the “Company”). Mr. Zook’s resignation was not the result of any disagreement regarding any matter relating to the Company’s operations, policies, or practices.


On April 28, 2022, Frederick Hrkac was appointed to the Board, effective as of the same date, to fill the vacancy on the Board as a result of Mr. Zook’s resignation, to serve as a director of the Board for a term expiring at the 2022 annual meeting of the Company’s stockholders, or until his successor is duly elected and qualified, or his earlier death, resignation or removal. For Mr. Hrkac’s service on the Board, Mr. Hrkac will receive compensation consistent with market practices of similarly situated companies that is consistent with the Company’s non-employee director compensation policy as may be then in effect. In addition, Mr. Hrkac was granted 50,000 nonqualified stock options with a term of ten years, 50% of which vested immediately upon Mr. Hrkac’s acceptance of the Board’s offer of employment and 50% of which shall vest on the first anniversary of his appointment, provided Mr. Hrkac is still serving as a director on such date.










Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.









Date: April 28, 2022

By: /s/ Kenneth L. Londoner                              

Name: Kenneth L. Londoner

Title: Executive Chairman







false 0001530766 0001530766 2022-04-22 2022-04-22